All Clinical Resources
Listen as expert Pri-Med faculty Dr. Ty Gluckman summarizes major take-home points about real work evidence and the impact of real word evidence on NOAC therapy for stroke prevention for patients with atrial fibrillation.
In this podcast episode, we will consider the rationale for using non-fasting labs to screen for ASCVD as well as review the controversies around their use and talk about the differential diagnosis of hypertriglyceridemia.
This podcast episode considers recent data that sheds light on how diet soda and artificial sweeteners might influence CNS outcomes, especially the risk for ischemic stroke.
Teaching patients lifestyle management strategies to improve health is no easy task. First steps involve increasing provider knowledge of the impact foods have on health. This episode discusses the latest evidence on different types of meat intake and meat associated compounds on health.
In this podcast episode, we will talk about how systolic hypertension affects outcomes, put into context a recent JACC systematic review paper on the topic and JNC 8. We will also discuss the Number Needed to Treat (NNT) and the Number Needed to Harm (NNH).
Oxygen is frequently given to patients routinely during the initial treatment of a myocardial infarction, but there is a lack of data to support or refute this. A recent systematic review found no benefit in patients who did not have baseline hypoxia. Oxygen therapy continues to be indicated for those with hypoxia and needs to be used with caution in COPD patients with carbon dioxide retention
This program will highlight a different approach to the treatment of heart failure with reduced ejection fraction (HFrEF). By targeting a mechanism of action aligned to pathophysiologic pathways, it is possible to reduce patient mortality and morbidity, while providing a proven safety and tolerability profile to help provide confidence in selecting your first-choice therapy for patients with HFrEF.
Join us as we examine the risk of hospitalization for heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF reduction in patients with T2D and established CV disease or multiple CV risk factors. We'll also discuss the results of the landmark DAPA-HF trial that support FARXIGA being the FIRST and ONLY FDA-approved sodium-glucose cotransporter 2 inhibitor (SGLT2) for patients with HF with reduced ejection fraction (HFrEF) with and without T2D.